- Home
- DT vs DVA Comparison
DT vs DVA Comparison
Compare DT & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DT
- DVA
- Stock Information
- Founded
- DT 2005
- DVA 1994
- Country
- DT United States
- DVA United States
- Employees
- DT N/A
- DVA N/A
- Industry
- DT Computer Software: Prepackaged Software
- DVA Misc Health and Biotechnology Services
- Sector
- DT Technology
- DVA Health Care
- Exchange
- DT Nasdaq
- DVA Nasdaq
- Market Cap
- DT 16.2B
- DVA 15.2B
- IPO Year
- DT 2019
- DVA 1995
- Fundamental
- Price
- DT $57.51
- DVA $177.52
- Analyst Decision
- DT Buy
- DVA Hold
- Analyst Count
- DT 25
- DVA 5
- Target Price
- DT $60.43
- DVA $153.40
- AVG Volume (30 Days)
- DT 2.9M
- DVA 537.1K
- Earning Date
- DT 01-30-2025
- DVA 02-11-2025
- Dividend Yield
- DT N/A
- DVA N/A
- EPS Growth
- DT N/A
- DVA 41.03
- EPS
- DT 0.54
- DVA 9.24
- Revenue
- DT $1,563,293,000.00
- DVA $12,666,614,000.00
- Revenue This Year
- DT $20.51
- DVA $6.18
- Revenue Next Year
- DT $15.55
- DVA $3.58
- P/E Ratio
- DT $106.45
- DVA $18.85
- Revenue Growth
- DT 20.58
- DVA 6.34
- 52 Week Low
- DT $39.42
- DVA $107.74
- 52 Week High
- DT $61.41
- DVA $178.75
- Technical
- Relative Strength Index (RSI)
- DT 63.88
- DVA 72.85
- Support Level
- DT $50.40
- DVA $167.57
- Resistance Level
- DT $59.02
- DVA $178.75
- Average True Range (ATR)
- DT 1.43
- DVA 3.75
- MACD
- DT 0.70
- DVA 1.43
- Stochastic Oscillator
- DT 79.41
- DVA 88.10
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.